Delcath Systems, Inc.'s Treatment for Liver Cancer is ''Featured Clinical Trial'' in Latest National Cancer Institute Cancer Bulletin

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq:DCTH) announced today that the Company’s Phase III study is the “Featured Clinical Trial” in the October 9th edition of the NCI Cancer Bulletin (Volume 4/Number 27). Delcath’s pivotal Phase III trial was approved under a Fast Track designation from the U.S. Food and Drug Administration (FDA), following its advancement directly from Phase I. This clinical trial is being conducted under a Special Protocol Assessment with the FDA. Delcath previously announced that the Company expects several sites to be added to the trial before year-end, with the NCI having agreed to act as the lead center in the trial.